USA flag logo/image

An Official Website of the United States Government

Recombinant Subunit Vaccine/Prevention of West Nile Vir*

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
66004
Program Year/Program:
2004 / SBIR
Agency Tracking Number:
AI052600
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
HAWAII BIOTECH, INC.
99-193 AIEA HEIGHTS DRIVE, SUITE 200 AIEA, HI -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2004
Title: Recombinant Subunit Vaccine/Prevention of West Nile Vir*
Agency: HHS
Contract: 9R44NS052139-02A1
Award Amount: $5,046,576.00
 

Abstract:

DESCRIPTION (provided by applicant): West Nile virus infection is an emerging infectious disease in the United States. The virus infects birds, which serve as the natural reservoir for the virus, in addition to humans and horses which are incidental hosts. It is an arthropod-borne virus, being transmitted by the Culex mosquito. Since 1999, the virus has rapidly spread throughout the continental U.S. Human cases of West Nile disease have been documented in 45 states of the continental U.S. including the west coast. In 2003, a total of 9,377 cases were reported with 244 deaths. About 30% of these cases showed indications of neuroinvasion. These clinical findings are significantly worse in elderly patients, in whom the case fatality rate approaches 30%. Currently, there is no approved commercially available vaccine for prevention of West Nile virus infection in humans. There is also no specific therapy for disease, only symptomatic treatment. In addition to natural infection, West Nile virus has the potential to be used as an agent of bioterrorism. The virus is currently listed as a category B priority pathogen by the NIAID. The ultimate goal of this research and development project is to produce a safe and effective vaccine for West Nile virus infection in humans. The candidate vaccine is a recombinant subunit vaccine in which the immunogens are a modified envelope protein plus a non-structural protein from the West Nile virus. The recombinant proteins are produced by a proprietary method of expression and purified by immunoaffinity chromatography. In phase I research, Hawaii Biotech demonstrated the immunogenicity and protective efficacy of this vaccine in an animal model of disease. The objectives of the present phase II research proposal are the pre-clinical development of the vaccine, including vaccine formulation and additional efficacy studies in animal models including non-human primates, as well as the production of well characterized antigens, and their use in GLP toxicology studies.

Principal Investigator:

Michael M. Lieberman
8087921309
STAFF@HIBIOTECH.COM

Business Contact:

Bower John
8087921333
JBOWER@HIBIOTECH.COM
Small Business Information at Submission:

HAWAII BIOTECH, INC.
99-193 AIEA HEIGHTS DRIVE, SUITE 200 AIEA, HI 96701

EIN/Tax ID: 990214983
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No